Partner Level
Company Headquarters
55 Corporate Drive, Bridgewater, NJ 08807
Visit Site

Company Overview


Sanofi’s focus on patients has driven our historical and ongoing strategy to create long-term value by researching and delivering innovative treatments. Sanofi Oncology’s heritage in oncology has given us an extensive knowledgebase that enriches our current research expertise. This experience encompasses a wide variety of cancer types, disease stages, patient populations, and patient needs. As a global healthcare company focused on patient needs, we are committed to attacking cancer on many fronts.

Today, our pipeline spans multiple therapeutic areas within oncology, across both solid tumors, hematology and transplant. We are an industry leader in the development of cytotoxic agents, which remain the foundation of cancer treatment. In addition to traditional chemotherapy, we are also investigating targeted agents and novel approaches, such as gene-focused therapy and drug-antibody combinations that may play an important role in advancing cancer management in the future.

While research into new therapeutic approaches is of vital importance, we cannot forget that cancer research is about people who are fighting for their lives. For this reason, our innovative patient awareness and support programs continue to expand. Through our collaborations, we strive to transform scientific innovation into hope and solutions for patients.

Testing for Gaucher Disease


Patient Assistance Programs

Patient Assistance Programs





ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

Educational Videos

This link features educational videos presented by Javier Pinilla, MD, PhD.

Javier Pinilla, MD, PhD

Dr. Pinilla-Ibarz has been at Moffitt since 2006 and holds the rank of Senior Member and Head of Lymphoma Section in the Department of Malignant Hematology. Dr. Pinilla-Ibarz received the 2016-17 Moffitt Physician of the Year Award. He was also the recipient of the ASCO young investigator award in 2003 and the ASCO career development award in 2007. Dr. Pinilla-Ibarz is nationally and internationally known for his expertise in chronic leukemia and he currently has over 120 peer-reviewed publications. He has received grant support through the Leukemia & Lymphoma Society and also from multiple industry partners. His clinical interests include chronic myeloid leukemia and chronic lymphoid leukemia. Dr. Pinilla-Ibarz’s laboratory is interested in implementing new immunotherapeutic strategies in the field of malignant hematology. He has received grant support through Leukemia and Lymphoma Society, NIH/NCI, Bank Head Cooley and from multiple industry partners.




  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.


ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).


Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.


  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose.

Please see full Prescribing Information, including Boxed WARNING.

MAT-US-2104298-v1.0 05/21


Prostate Cancer Awareness Month


© 2021 FLASCO | Premium Website Design by The HDG